SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt informs about press release

30 Mar 2026 Evaluate

Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release – ‘Wockhardt’s Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO’s Subject Expert Committee for Treatment of Gram-Negative Infections’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.

Wockhardt Share Price

1631.45 24.55 (1.53%)
11-May-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1877.25
Dr. Reddys Lab 1289.75
Cipla 1340.25
Zydus Lifesciences 946.75
Lupin 2240.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×